Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck Foundation and Ministry of Gender Equality of Mauritius Train the Journalists to Raise Awareness on Sensitive Social and Health Issues ...

Senator Dr. Rasha Kelej emphasized the critical role that journalists, media professionals, and storytellers play in shaping ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Merck has announced the acquisition of SpringWorks, which is expected to close this year, for an enterprise value of EUR 3 billion. While the deal appears expensive at an 18 times price/sales multiple ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.